Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11, 191–207 (2007).
   PubMedGoogle Scholar
• Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998–2003. Prev. Chronic Dis.5(3), A74 (2008).
   Google Scholar
• Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol.40, 225–235 (2005).
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology126, 1005–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Craxì A. Hepatocellular cancer: optimal strategies for screening and surveillance. Dig. Dis.27(2), 142–147 (2009).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37, 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther.23, 1535–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10, 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarz RE, Abou-Alfa GK, Geschwind JF et al.; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford)12(5), 313–320 (2010).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma: an update. Hepatology53(3), 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am. J. Gastroenterol.104(7), 1802–1829 (2009).
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg.60, 646–649 (1973).
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liv. Int. doi:10.1111/j.1478–3231 .2011.02629.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Cabibbo G, Enea M, Attanasio M et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology51, 1274–1283 (2010).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis.19(3), 329–338 (1999).
   PubMed Web of Science ®Google Scholar
• Cottone M, Virdone R, Fusco G et al. Asymptomatic hepatocellular carcinoma in Child’s A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology96(6), 1566–1571 (1999).
   Google Scholar
• Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet373(9664), 614–616 (2009).
   PubMed Web of Science ®Google Scholar
• Samuel M, Chow PKH, Chan Shih-Yen E et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst. Rev.1, CD001199 (2009).
   Google Scholar
• Lau WY, Lai ECH. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat. Dis. Int.7, 237–257 (2008).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology42, 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int. J. Clin. Pract.64(8), 1034–1041 (2010).
   PubMed Web of Science ®Google Scholar
• Marrero JA, Lencioni R, Kudo M et al. Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 4001).
   Google Scholar
• Peck-Radosavljevic M, Greten TF, Lammer J et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol.22(4), 391–398 (2010).
   PubMed Web of Science ®Google Scholar
• Burak KW. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge? Oncology (Williston Park)25(3), 296, 298, 300 (2011).
   PubMed Web of Science ®Google Scholar
• Bolondi L, Caspary W, Bennouna J et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25–27 January 2008.
   Google Scholar
• Cabibbo G, Di Marco V, Cammà C et al. Sorafenib for hepatocellular carcinoma: a practice experience. ILCA 2010 Book of Abstracts162 (2010).
   Google Scholar
• Di Maio M, Daniele B, Perrone F. Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nat. Rev. Clin. Oncol.6(9), 505–506 (2009).
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist13(9), 1001–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist4, 1–10 (1999).
   PubMedGoogle Scholar
• Curt GA, Breitbart W, Cella D, Scherr SL, Portenoy RK, Vogelzang NJ. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist5(5), 353–360 (2000).
   PubMedGoogle Scholar
• Pressiani T, Rimassa L, Boni C et al. Phase II randomized trial on dose-escalated sorafenib versus best supportive care in patients with advanced hepatocellular carcinoma with disease prosgression on prior sorafenib treatment. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 4115).
   Google Scholar
• Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer (2011) (In Press).
   PubMedGoogle Scholar
• Erhardt A, Kollgs FT, Dollinger M et al. Sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma – final results of the Socrates trial. J. Hepatol.54, S35 (2011).
   Google Scholar
• Chung Y, Kim B, Chen C et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis. J. Clin. Onc.28(Suppl.), 4026 (2010).
   Google Scholar
• Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Scan. J. Gastroenterol.45, 511–512 (2010).
   PubMed Web of Science ®Google Scholar
• Dufour JF, Hoppe H, Heim MH et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patient with hepatocellular carcinoma: results of a Phase I study. Oncologist15, 1198–1204 (2010).
   PubMed Web of Science ®Google Scholar